Patents by Inventor Paolo Costantino
Paolo Costantino has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220152183Abstract: The invention is in the field of vaccines and relates to oligomers having a selected degree of polymerization, obtained by connecting together a number of carbocyclic repeating units, and to conjugated derivatives thereof. The oligomers and conjugated derivatives thereof of the invention also have a selected degree of acetylation. The derivatives of the invention are useful for the preparation of immunogenic compositions, e.g. in the form of a vaccine.Type: ApplicationFiled: March 6, 2020Publication date: May 19, 2022Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Roberto ADAMO, Francesco BERTI, Paolo COSTANTINO, Luigi LAY
-
Publication number: 20220089627Abstract: The invention provides a method for releasing capsular polysaccharide from S. aureus type 5 or type 8 cells, comprising the step of treating the cells with acid. The invention further provides a process for purifying capsular polysaccharide from S. aureus type 5 or type 8 cells comprising this method. Other processing steps may be included in the process, such as enzymatic treatment, e.g. to remove nucleic acid, protein and/or peptidoglycan contaminants; diafiltration, e.g. to remove low molecular weight contaminants; anion exchange chromatography, e.g. to remove residual protein; and concentration.Type: ApplicationFiled: November 17, 2021Publication date: March 24, 2022Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Paolo COSTANTINO, Maria Rosaria ROMANO, Francesco BERTI
-
Patent number: 11208424Abstract: The invention provides a method for releasing capsular polysaccharide from S. aureus type 5 or type 8 cells, comprising the step of treating the cells with acid. The invention further provides a process for purifying capsular polysaccharide from S. aureus type 5 or type 8 cells comprising this method. Other processing steps may be included in the process, such as enzymatic treatment, e.g. to remove nucleic acid, protein and/or peptidoglycan contaminants; diafiltration, e.g. to remove low molecular weight contaminants; anion exchange chromatography, e.g. to remove residual protein; and concentration. The invention also provides a composition comprising a S. aureus type 5 or type 8 capsular polysaccharide, obtainable by any of the processes of the invention.Type: GrantFiled: February 13, 2019Date of Patent: December 28, 2021Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Paolo Costantino, Maria Rosaria Romano, Francesco Berti
-
Patent number: 11065323Abstract: A process for purifying a Streptococcus pyogenes GAS carbohydrate comprising a step of anionic exchange chromatography. The process provides a good yield of GAS carbohydrate. The saccharides of the invention have low levels of hyaluronic acid, protein and nucleic acid contamination.Type: GrantFiled: October 27, 2009Date of Patent: July 20, 2021Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Paolo Costantino, Francesco Berti, Anna Kabanova, Maria Rosaria Romano
-
Patent number: 10736959Abstract: The invention provides a process for preparing a conjugate of a S. aureus type 5 or type 8 capsular polysaccharide and a carrier molecule, comprising the steps of: (a) depolymerising the capsular polysaccharide, to give a polysaccharide fragment; (b) oxidising the fragment in order to introduce an aldehyde group into at least one saccharide residue in the fragment, to give an oxidised saccharide residue; and (c) coupling the oxidised saccharide residue to a carrier molecule via the aldehyde group, thereby giving the conjugate. The coupling in step (c) may be direct, or may be via a linker molecule. The invention also provides a conjugate obtained or obtainable by this process.Type: GrantFiled: November 10, 2017Date of Patent: August 11, 2020Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Francesco Berti, Paolo Costantino, Maria Rosaria Romano
-
Patent number: 10716841Abstract: Precipitated bacterial capsular polysaccharides can be efficiently re-solubilised using alcohols as solvents. The invention provides a process for purifying a bacterial capsular polysaccharide, comprising the steps of (a) precipitation of said polysaccharide, followed by (b) solubilisation of the precipitated polysaccharide using ethanol. CTAB can be used for step (a). The material obtained, preferably following hydrolysis and sizing, can be conjugated to a carrier protein and formulated as a vaccine. Also, in vaccines comprising saccharides from both serogroups A and C, the invention provides that the ratio (w/w) of Men A saccharide:MenC saccharide is >1.Type: GrantFiled: October 31, 2016Date of Patent: July 21, 2020Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventor: Paolo Costantino
-
Patent number: 10668143Abstract: The invention provides a conjugate of a Neisseria meningitidis serogroup X capsular polysaccharide and a carrier molecule. The conjugate is typically made by (a) oxidising a primary hydroxyl group in the capsular polysaccharide, to give an oxidised polysaccharide with an aldehyde group; and (b) coupling the oxidised polysaccharide to a carrier molecule via the aldehyde group, thereby giving the conjugate. The conjugate may be part of an immunogenic composition. This composition may comprise one or more further antigens, particularly capsular polysaccharides from serogroups A, W135, C and Y and conjugated forms thereof. The composition may be in an aqueous formulation. The composition is useful as a vaccine, e.g. for raising an immune response in a mammal. The invention also provides processes for making the conjugate.Type: GrantFiled: November 7, 2018Date of Patent: June 2, 2020Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Maria Rosaria Romano, Francesca Micoli, Francesco Berti, Roberto Adamo, Paolo Costantino
-
Patent number: 10668142Abstract: An injectable immunogenic composition comprising capsular saccharides from at least two of serogroups A, C, W135 and Y of Neisseria meningitidis, wherein said capsular saccharides are conjugated to carrier protein(s) and/or are oligosaccharides, and wherein (i) the composition comprises <50 ?g meningococcal saccharide per dose, and/or (ii) the composition further comprises an antigen from one or more of: (a) serogroup B N. meningitidis; (b) Haemophilus influenzae type B; and/or (c) Streptococcus pneumoniae. Saccharide antigens in the compositions are generally conjugated to a carrier.Type: GrantFiled: April 25, 2018Date of Patent: June 2, 2020Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventor: Paolo Costantino
-
Publication number: 20190169216Abstract: The invention provides a method for releasing capsular polysaccharide from S. aureus type 5 or type 8 cells, comprising the step of treating the cells with acid. The invention further provides a process for purifying capsular polysaccharide from S. aureus type 5 or type 8 cells comprising this method. Other processing steps may be included in the process, such as enzymatic treatment, e.g. to remove nucleic acid, protein and/or peptidoglycan contaminants; diafiltration, e.g. to remove low molecular weight contaminants; anion exchange chromatography, e.g. to remove residual protein; and concentration.Type: ApplicationFiled: February 13, 2019Publication date: June 6, 2019Applicant: GLAXOSMITHKLINE BIOLOGICALS, S.A.Inventors: Paolo COSTANTINO, Maria Rosaria ROMANO, Francesco BERTI
-
Patent number: 10272147Abstract: An injectable immunogenic composition comprising capsular saccharides from at least two of serogroups A, C, W135 and Y of Neisseria meningitidis, wherein said capsular saccharides are conjugated to carrier protein(s) and/or are oligosaccharides, and wherein (i) the composition comprises <50 ?g meningococcal saccharide per dose, and/or (ii) the composition further comprises an antigen from one or more of: (a) serogroup B N. meningitidis; (b) Haemophilus influenzae type B; and/or (c) Streptococcus pneumoniae. Saccharide antigens in the compositions are generally conjugated to a carrier.Type: GrantFiled: January 30, 2004Date of Patent: April 30, 2019Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventor: Paolo Costantino
-
Publication number: 20190060437Abstract: The invention provides a conjugate of a Neisseria meningitidis serogroup X capsular polysaccharide and a carrier molecule. The conjugate is typically made by (a) oxidising a primary hydroxyl group in the capsular polysaccharide, to give an oxidised polysaccharide with an aldehyde group; and (b) coupling the oxidised polysaccharide to a carrier molecule via the aldehyde group, thereby giving the conjugate. The conjugate may be part of an immunogenic composition. This composition may comprise one or more further antigens, particularly capsular polysaccharides from serogroups A, W135, C and Y and conjugated forms thereof. The composition may be in an aqueous formulation. The composition is useful as a vaccine, e.g. for raising an immune response in a mammal. The invention also provides processes for making the conjugate.Type: ApplicationFiled: November 7, 2018Publication date: February 28, 2019Applicant: GLAXOSMITHKLINE BIOLOGICALS, S.A.Inventors: Maria Rosaria Romano, Francesca Micoli, Francesco Berti, Roberto Adamo, Paolo Costantino
-
Patent number: 10172928Abstract: A purification method for the capsular polysaccharide of type II GBS in which the capsular polysaccharide is filtered using a membrane with a cut-off of less than 30 kDa.Type: GrantFiled: December 17, 2015Date of Patent: January 8, 2019Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Francesco Berti, Paolo Costantino, Maria Rosaria Romano
-
Patent number: 10124051Abstract: The invention provides a conjugate of a Neisseria meningitidis serogroup X capsular polysaccharide and a carrier molecule. The conjugate is typically made by (a) oxidizing a primary hydroxyl group in the capsular polysaccharide, to give an oxidized polysaccharide with an aldehyde group; and (b) coupling the oxidized polysaccharide to a carrier molecule via the aldehyde group, thereby giving the conjugate. The conjugate may be part of an immunogenic composition. This composition may comprise one or more further antigens, particularly capsular polysaccharides from serogroups A, W135, C and Y and conjugated forms thereof. The composition may be in an aqueous formulation. The composition is useful as a vaccine, e.g. for raising an immune response in a mammal. The invention also provides processes for making the conjugate.Type: GrantFiled: May 22, 2013Date of Patent: November 13, 2018Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Maria Rosaria Romano, Francesca Micoli, Francesco Berti, Roberto Adamo, Paolo Costantino
-
Publication number: 20180243395Abstract: An injectable immunogenic composition comprising capsular saccharides from at least two of serogroups A, C, W135 and Y of Neisseria meningitidis, wherein said capsular saccharides are conjugated to carrier protein(s) and/or are oligosaccharides, and wherein (i) the composition comprises <50 ?g meningococcal saccharide per dose, and/or (ii) the composition further comprises an antigen from one or more of: (a) serogroup B N.meningitidis; (b) Haemophilus influenzae type B; and/or (c) Streptococcus pneumoniae. Saccharide antigens in the compositions are generally conjugated to a carrier.Type: ApplicationFiled: April 25, 2018Publication date: August 30, 2018Applicant: GLAXOSMITHKLINE BIOLOGICALS, SAInventor: Paolo COSTANTINO
-
Publication number: 20180153983Abstract: The invention provides a process for preparing a conjugate of a S.aureus type 5 or type 8 capsular polysaccharide and a carrier molecule, comprising the steps of: (a) depolymerising the capsular polysaccharide, to give a polysaccharide fragment; (b) oxidising the fragment in order to introduce an aldehyde group into at least one saccharide residue in the fragment, to give an oxidised saccharide residue; and (c) coupling the oxidised saccharide residue to a carrier molecule via the aldehyde group, thereby giving the conjugate. The coupling in step (c) may be direct, or may be via a linker molecule. The invention also provides a conjugate obtained or obtainable by this process.Type: ApplicationFiled: November 10, 2017Publication date: June 7, 2018Applicant: GLAXOSMITHKLINE BIOLOGICALS, SAInventors: Francesco BERTI, Paolo COSTANTINO, Maria Rosaria ROMANO
-
Patent number: 9981031Abstract: An injectable immunogenic composition comprising capsular saccharides from at least two of serogroups A, C, W135 and Y of Neisseria meningitidis, wherein said capsular saccharides are conjugated to carrier protein(s) and/or are oligosaccharides, and wherein (i) the composition comprises <50 ?g meningococcal saccharide per dose, and/or (ii) the composition further comprises an antigen from one or more of (a) serogroup B N. meningitidis; (b) Haemophilus influenzae type B; and/or (c) Streptococcus pneumoniae. Saccharide antigens in the compositions are generally conjugated to a carrier.Type: GrantFiled: August 18, 2016Date of Patent: May 29, 2018Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventor: Paolo Costantino
-
Publication number: 20180036402Abstract: A method of immunization against Group B Streptococcus infection, using an immunogenic composition conjugates of GBS capsular saccharide conjugated to carrier proteins.Type: ApplicationFiled: September 15, 2017Publication date: February 8, 2018Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Francesco BERTI, Mario CONTORNI, Paolo COSTANTINO, Oretta FINCO, Guido GRANDI, Domenico MAIONE, John TELFORD
-
Patent number: 9839686Abstract: The invention provides a process for preparing a conjugate of a S. aureus type 8 capsular polysaccharide and a carrier molecule, comprising the steps of: (a) depolymerising the capsular polysaccharide, to give a polysaccharide fragment; (b) oxidising the fragment in order to introduce an aldehyde group into at least one saccharide residue in the fragment, to give an oxidised saccharide residue; and (c) coupling the oxidised saccharide residue to a carrier molecule via the aldehyde group, thereby giving the conjugate. The coupling in step (c) may be direct, or may be via a linker molecule. The invention also provides a conjugate obtained or obtainable by this process.Type: GrantFiled: February 2, 2015Date of Patent: December 12, 2017Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Francesco Berti, Paolo Costantino, Maria Rosaria Romano
-
Publication number: 20170348408Abstract: A purification method for the capsular polysaccharide of type II GBS in which the capsular polysaccharide is filtered using a membrane with a cut-off of less than 30 kDa.Type: ApplicationFiled: December 17, 2015Publication date: December 7, 2017Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Francesco BERTI, Paolo COSTANTINO, Maria Rosaria ROMANO
-
Patent number: 9827301Abstract: Capsular saccharides derived from serogroups W135 and Y of Neisseria meningitidis have altered levels of O-acetylation at the 7 and 9 positions of their sialic acid residues, and can be used to make immunogenic compositions. Relative to unmodified native saccharides, derivatives of the invention are preferentially selected during conjugation to carrier proteins, and conjugates of the derivatives show improved immunogenicity compared to native polysaccharides.Type: GrantFiled: May 1, 2014Date of Patent: November 28, 2017Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Paolo Costantino, Francesco Berti